Works by List, Alan F.

Results: 72

Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis.

Published in:

1986

By:

Doll, Donald C.;
List, Alan F.;
Greco, F. Anthony;
Hainsworth, John D.;
Hande, Kenneth R.;
Johnson, David H.;
Doll, D C;
List, A F;
Greco, F A;
Hainsworth, J D;
Hande, K R;
Johnson, D H

Publication type:

journal article

The 5q- syndrome: biology and treatment.

Published in:

2011

By:

Padron, Eric;
Komrokji, Rami;
List, Alan;
List, Alan F

Publication type:

journal article

Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results from an Internet-Based Survey.

Published in:

Oncologist, 2011, v. 16, n. 6, p. 904, doi. 10.1634/theoncologist.2010-0199

By:

Sekeres, Mikkael A.;
Maciejewski, Jaroslaw P.;
List, Alan F.;
Steensma, David P.;
Artz, Andrew;
Swern, Arlene S.;
Scribner, Paul;
Huber, John;
Stone, Richard

Publication type:

Article

A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.

Published in:

Leukemia & Lymphoma, 2020, v. 61, n. 8, p. 1901, doi. 10.1080/10428194.2020.1751841

By:

Duong, Vu H.;
Al Ali, Najla;
Zhang, Ling;
Padron, Eric;
Sallman, David;
Lancet, Jeffrey E.;
List, Alan F.;
Komrokji, Rami S.

Publication type:

Article

Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1.

Published in:

Leukemia & Lymphoma, 2020, v. 61, n. 6, p. 1395, doi. 10.1080/10428194.2020.1723016

By:

Nguyen, Lynh;
Zhang, Xiaohui;
Roberts, Evans;
Yun, Seongseok;
McGraw, Kathy;
Abraham, Ivo;
Song, Jinming;
Braswell, Diana;
Qin, Dahui;
Sallman, David A.;
Lancet, Jeffrey E.;
List, Alan F.;
Moscinski, Lynn C.;
Padron, Eric;
Zhang, Ling

Publication type:

Article

The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.

Published in:

Leukemia & Lymphoma, 2017, v. 58, n. 8, p. 1777, doi. 10.1080/10428194.2016.1266625

By:

Zhang, Ling;
McGraw, Kathy L.;
Sallman, David A.;
List, Alan F.

Publication type:

Article

A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution.

Published in:

Acta Haematologica, 2015, v. 133, n. 2, p. 249, doi. 10.1159/000365877

By:

Peker, Deniz;
Padron, Eric;
Bennett, John M.;
Zhang, Xiaohui;
Horna, Pedro;
Epling-Burnette, Pearlie K.;
Lancet, Jeffrey E.;
Pinilla-Ibarz, Javier;
Moscinski, Lynn;
List, alan F.;
Komrokji, Rami S.;
Zhang, Ling

Publication type:

Article

B-Lymphoblastic Leukemia/Lymphoma Associated with t(8;13)(p11;q12)/ZMYM2 (ZNF198)-FGFR1: Rare Case and Review of the Literature.

Published in:

Acta Haematologica, 2013, v. 130, n. 3, p. 127, doi. 10.1159/000347030

By:

Trimaldi, Janese;
Carballido, Estrella M.;
Bowers, Jeremy W.;
anguiano, arturo L.;
Zhang, Zhong J.;
Shah, Bijal D.;
Bruno, Salvador;
List, alan F.;
Moscinski, Lynn C.;
Grady, Terrence;
agosti, Steven J.;
Kang, Loveleen;
Zhang, Ling

Publication type:

Article

Driver mutation‐specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Published in:

American Journal of Hematology, 2019, v. 94, n. 12, p. E314, doi. 10.1002/ajh.25625

By:

Kuykendall, Andrew T.;
Talati, Chetasi;
Padron, Eric;
Sweet, Kendra;
Lancet, Jeffrey E.;
List, Alan F.;
Sallman, David;
Komrokji, Rami S.

Publication type:

Article

Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.

Published in:

American Journal of Hematology, 2019, v. 94, n. 1, p. 87, doi. 10.1002/ajh.25335

By:

Kuykendall, Andrew T.;
Talati, Chetasi;
Padron, Eric;
Sweet, Kendra;
Sallman, David;
List, Alan F.;
Lancet, Jeffrey E.;
Komrokji, Rami S.

Publication type:

Article

Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.

Published in:

American Journal of Hematology, 2017, v. 92, n. 3, p. 232, doi. 10.1002/ajh.24627

By:

Griffin, Patrick T.;
Komrokji, Rami S.;
Sweet, Kendra;
Al Ali, Najla H.;
Padron, Eric;
Kubal, Timothy E.;
List, Alan F.;
Lancet, Jeffrey E.

Publication type:

Article

Autoimmune diseases and myelodysplastic syndromes.

Published in:

American Journal of Hematology, 2016, v. 91, n. 5, p. E280, doi. 10.1002/ajh.24333

By:

Komrokji, Rami S.;
Kulasekararaj, Austin;
Al Ali, Najla H.;
Kordasti, Shahram;
Bart-Smith, Emily;
Craig, Benjamin M.;
Padron, Eric;
Zhang, Ling;
Lancet, Jeffrey E.;
Pinilla-Ibarz, Javier;
List, Alan F.;
Mufti, Ghulam J.;
Epling-Burnette, Pearlie K.

Publication type:

Article

Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?

Published in:

American Journal of Hematology, 2015, v. 90, n. 11, p. 1036, doi. 10.1002/ajh.24173

By:

Zeidan, Amer M.;
Sekeres, Mikkael A.;
Wang, Xiao-Feng;
Al Ali, Najla;
Garcia-Manero, Guillermo;
Steensma, David P.;
Roboz, Gail;
Barnard, John;
Padron, Eric;
DeZern, Amy;
Maciejewski, Jaroslaw P.;
List, Alan F.;
Komrokji, Rami S.

Publication type:

Article

A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.

Published in:

American Journal of Hematology, 2015, v. 90, n. 9, p. 796, doi. 10.1002/ajh.24087

By:

Griffin, Patrick T.;
Komrokji, Rami S.;
De Castro, Carlos M.;
Rizzieri, David A.;
Melchert, Magda;
List, Alan F.;
Lancet, Jeffrey E.

Publication type:

Article

Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.

Published in:

American Journal of Hematology, 2014, v. 89, n. 8, p. 809, doi. 10.1002/ajh.23749

By:

Komrokji, Rami S.;
Padron, Eric;
Yu, Daohai;
Fulp, William J.;
Rodriguez, Yuraima;
Tinsley, Sara;
List, Alan F.;
Lancet, Jeffrey E.

Publication type:

Article

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Published in:

American Journal of Hematology, 2013, v. 88, n. 7, p. 566, doi. 10.1002/ajh.23454

By:

Mishra, Asmita;
Corrales-Yepez, Maria;
Ali, Najla Al;
Kharfan-Dabaja, Mohamed;
Padron, Eric;
Zhang, Ling;
Epling-Burnette, Pearlie K.;
Pinilla-Ibarz, Javier;
Lancet, Jeffrey E.;
List, Alan F.;
Komrokji, Rami S.

Publication type:

Article

Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.

Published in:

American Journal of Hematology, 2012, v. 87, n. 11, p. 1006, doi. 10.1002/ajh.23303

By:

Komrokji, Rami S.;
Corrales-Yepez, Maria;
Kharfan-Dabaja, Mohamed A.;
Al Ali, Najla H.;
Padron, Eric;
Rollison, Dana E.;
Pinilla-Ibarz, Javier;
Zhang, Ling;
Epling-Burnette, Pearlie K.;
Lancet, Jeffrey E.;
List, Alan F.

Publication type:

Article

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

Published in:

American Journal of Hematology, 2011, v. 86, n. 1, p. 102, doi. 10.1002/ajh.21891

By:

Sekeres, Mikkael A.;
O'Keefe, Christine;
List, Alan F.;
Paulic, Katarina;
Afable, Manuel;
Englehaupt, Ricki;
Maciejewski, Jaroslaw P.

Publication type:

Article

Selective variegated methylation of the p15 CpG island in acute myeloid leukemia.

Published in:

International Journal of Cancer, 1998, v. 78, n. 5, p. 561, doi. 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R

By:

Dodge, Jonathan E.;
List, Alan F.;
Futscher, Bernard W.

Publication type:

Article

Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.

Published in:

2020

By:

Sallman, David A.;
Barnard, John;
Al Ali, Najla H.;
Garcia-Manero, Guillermo;
Sekeres, Mikkael A.;
DeZern, Amy;
Steensma, David P.;
Roboz, Gail;
Jabbour, Elias;
Maciejewski, Jaroslaw P.;
Pierce, Sherry;
Padron, Eric;
Lancet, Jeffrey E.;
Kantarjian, Hagop;
List, Alan F.;
Komrokji, Rami S.

Publication type:

journal article

SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.

Published in:

2020

By:

Zhang, Qing;
Haider, Mintallah;
Al Ali, Najla H.;
Lancet, Jeffrey E.;
Epling-Burnette, Pearlie K.;
List, Alan F.;
Padron, Eric;
Komrokji, Rami S.

Publication type:

journal article

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.

Published in:

2019

By:

Komrokji, Rami S.;
Wei, Sheng;
Mailloux, Adam W.;
Zhang, Ling;
Padron, Eric;
Sallman, David;
Lancet, Jeffrey E.;
Tinsley, Sara;
Nardelli, Lisa A.;
Pinilla-Ibarz, Javier;
Epling-Burnette, Pearlie K.;
List, Alan F.

Publication type:

journal article

SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.

Published in:

2018

By:

Talati, Chetasi;
Sallman, David;
List, Alan F.

Publication type:

journal article

When Two Roads Diverge: Genetically Inspired Prognostic Scoring System (GIPSS) Outperforms DIPSS in Myelofibrosis Patients where the Two Risk Models Widely Differ.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S266, doi. 10.1016/j.clml.2018.07.183

By:

Kuykendall, Andrew;
Talati, Chetasi;
Padron, Eric;
Sweet, Kendra;
Sallman, David;
List, Alan F.;
Lancet, Jeffrey E.;
Komrokji, Rami

Publication type:

Article

Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S201, doi. 10.1016/j.clml.2018.07.051

By:

Talati, Chetasi;
Kuykendall, Andrew;
Al Ali, Najla;
Kim, Jongphil;
Sehovic, Marina;
Sallman, David;
List, Alan F.;
Komrokji, Rami;
Extermann, Martine;
Djulbegovic, Benjamin;
Sweet, Kendra;
Lancet, Jeffrey

Publication type:

Article

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Published in:

2017

By:

Kuykendall, Andrew T.;
Talati, Chetasi;
Al Ali, Najla;
Sweet, Kendra;
Padron, Eric;
Sallman, David A.;
Lancet, Jeffrey E.;
List, Alan F.;
Zuckerman, Kenneth S.;
Komrokji, Rami S.

Publication type:

journal article

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.

Published in:

2017

By:

Mirza, Abu-Sayeef;
Lancet, Jeffrey E.;
Sweet, Kendra;
Padron, Eric;
Pinilla-Ibarz, Javier;
Nardelli, Lisa;
Cubitt, Christopher;
List, Alan F.;
Komrokji, Rami S.

Publication type:

journal article

Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.

Published in:

2017

By:

Apuri, Susmitha;
Al Ali, Najla;
Padron, Eric;
Lancet, Jeffrey E.;
List, Alan F.;
Komrokji, Rami S.

Publication type:

journal article

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.

Published in:

2016

By:

Ramadan, Hanadi;
Duong, Vu H.;
Al Ali, Najla;
Padron, Eric;
Zhang, Ling;
Lancet, Jeffrey E.;
List, Alan F.;
Komrokji, Rami S.

Publication type:

journal article

Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology.

Published in:

2016

By:

List, Alan F.;
Kantarjian, Hagop;
Freireich, Emil J.

Publication type:

Editorial

Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.

Published in:

2013

By:

Duong, Vu H;
Lin, Karen;
Reljic, Tea;
Kumar, Ambuj;
Al Ali, Najla H;
Lancet, Jeffrey E;
List, Alan F;
Komrokji, Rami S

Publication type:

Journal Article

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Published in:

2018

By:

Kuykendall, Andrew T.;
Shah, Savan;
Talati, Chetasi;
Al Ali, Najla;
Sweet, Kendra;
Padron, Eric;
Sallman, David A.;
Lancet, Jeffrey E.;
List, Alan F.;
Zuckerman, Kenneth S.;
Komrokji, Rami S.

Publication type:

journal article

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.

Published in:

2018

By:

Duong, Vu H.;
Padron, Eric;
Al Ali, Najla H.;
Lancet, Jeffrey E.;
Hall, Jeff;
Kwok, Brian;
Zhang, Ling;
Epling-Burnette, Pearlie K.;
List, Alan F.;
Komrokji, Rami S.

Publication type:

journal article

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.

Published in:

Biomarker Research, 2020, v. 8, n. 1, p. 1, doi. 10.1186/s40364-020-00208-1

By:

Pogosova-Agadjanyan, Era L.;
Moseley, Anna;
Othus, Megan;
Appelbaum, Frederick R.;
Chauncey, Thomas R.;
Chen, I-Ming L.;
Erba, Harry P.;
Godwin, John E.;
Jenkins, Isaac C.;
Fang, Min;
Huynh, Mike;
Kopecky, Kenneth J.;
List, Alan F.;
Naru, Jasmine;
Radich, Jerald P.;
Stevens, Emily;
Willborg, Brooke E.;
Willman, Cheryl L.;
Wood, Brent L.;
Zhang, Qing

Publication type:

Article

The Clinical Management of Chronic Myelomonocytic Leukemia.

Published in:

Clinical Advances in Hematology & Oncology, 2014, v. 12, n. 3, p. 172

By:

Padron, Eric;
Komrokji, Rami;
List, Alan F.

Publication type:

Article

Immunomodulatory therapy for myelodysplastic syndromes.

Published in:

2007

By:

Sokol, Lubomir;
List, Alan F

Publication type:

journal article

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium.

Published in:

Cancer (0008543X), 2015, v. 121, n. 6, p. 876, doi. 10.1002/cncr.29145

By:

Jabbour, Elias J.;
Garcia‐Manero, Guillermo;
Strati, Paolo;
Mishra, Asmita;
Al Ali, Najla H.;
Padron, Eric;
Lancet, Jeffrey;
Kadia, Tapan;
Daver, Naval;
O'Brien, Susan;
Steensma, David P.;
Sekeres, Mikkael A.;
Gore, Steven D.;
Dezern, Amy;
Roboz, Gail J.;
List, Alan F.;
Kantarjian, Hagop M.;
Komrokji, Rami S.

Publication type:

Article

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes.

Published in:

Cancer (0008543X), 2014, v. 120, n. 11, p. 1670, doi. 10.1002/cncr.28631

By:

Steensma, David P.;
Komrokji, Rami S.;
Stone, Richard M.;
List, Alan F.;
Garcia‐Manero, Guillermo;
Huber, John M.;
Dennison, Betsy;
Sekeres, Mikkael A.

Publication type:

Article

Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.

Published in:

Cancer (0008543X), 2012, v. 118, n. 10, p. 2659, doi. 10.1002/cncr.26567

By:

Komrokji, Rami S.;
Corrales-Yepez, Maria;
Al Ali, Najla;
Kharfan-Dabaja, Mohammad;
Padron, Eric;
Fields, Teresa;
Lancet, Jeffrey E.;
List, Alan F.

Publication type:

Article

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.

Published in:

Cancer (0008543X), 2012, v. 118, n. 8, p. 2138, doi. 10.1002/cncr.26469

By:

Raza, Azra;
Galili, Naomi;
Smith, Scott E.;
Godwin, John;
Boccia, Ralph V.;
Myint, Han;
Mahadevan, Daruka;
Mulford, Deborah;
Rarick, Mark;
Brown, Gail L.;
Schaar, Dale;
Faderl, Stefan;
Komrokji, Rami S.;
List, Alan F.;
Sekeres, Mikkael

Publication type:

Article

ALPHA-INTERFERON IN THE TREATMENT OF IDIOPATHIC MYELOFIBROSIS.

Published in:

British Journal of Haematology, 1992, v. 80, n. 4, p. 566, doi. 10.1111/j.1365-2141.1992.tb04580.x

By:

List, Alan F.;
Doll, Donald C.

Publication type:

Article

Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype.

Published in:

British Journal of Haematology, 1991, v. 78, n. 1, p. 28, doi. 10.1111/j.1365-2141.1991.tb04378.x

By:

List, Alan F.;
Spier, Catherine M.;
Cline, Ann;
Doll, Donald C.;
Garewal, Harinder;
Morgan, Rodman;
Sandberg, Avery A.

Publication type:

Article

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia.

Published in:

Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-62345-9

By:

Michelson, Andrew P.;
McDonough, Shannon;
Willman, Cheryl L.;
Koegle, Eric R.;
Godwin, John E.;
Petersdorf, Stephen H.;
List, Alan F.;
Othus, Megan;
Appelbaum, Frederick R.;
Radich, Jerald P.;
Ganapathi, Mahrukh K.;
Advani, Anjali S.;
Ganapathi, Ram N.

Publication type:

Article

Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?

Published in:

Expert Review of Hematology, 2013, v. 6, n. 5, p. 485, doi. 10.1586/17474086.2013.827884

By:

Duong, Vu H;
Padron, Eric;
List, Alan F;
Komrokji, Rami S

Publication type:

Article

Evans' syndrome associated with microcystic adenoma of the pancreas.

Published in:

1987

By:

Doll, Donald C.;
List, Alan F.;
Yarbro, John W.;
Doll, D C;
List, A F;
Yarbro, J W

Publication type:

journal article

Ranitidine--Induced Granulocytopenia: Recurrence with Cimetidine Administration.

Published in:

Annals of Internal Medicine, 1988, v. 108, n. 4, p. 566, doi. 10.7326/0003-4819-108-4-566

By:

List, Alan F.;
Beaird, David H.;
Kummet, Thomas

Publication type:

Article

Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: association with Epstein-Barr virus.

Published in:

1986

By:

List, Alan F.;
Greer, John P.;
Cousar, John B.;
Stein, Richard S.;
Flexner, John M.;
Sinangil, Faruk;
Davis, Jack;
Volsky, David J.;
Purtilo, David T.;
List, A F;
Greer, J P;
Cousar, J B;
Stein, R S;
Flexner, J M;
Sinangil, F;
Davis, J;
Volsky, D J;
Purtilo, D T

Publication type:

journal article

Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.

Published in:

British Journal of Haematology, 2019, v. 184, n. 3, p. 450, doi. 10.1111/bjh.15099

By:

McGraw, Kathy L.;
Nguyen, Johnny;
Al Ali, Najla H.;
Komrokji, Rami S.;
Sallman, David;
Zhang, Xiaohui;
Song, Jinming;
Padron, Eric;
Lancet, Jeffrey E.;
Moscinski, Lynn C.;
List, Alan F.;
Zhang, Ling

Publication type:

Article

SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.

Published in:

British Journal of Haematology, 2014, v. 167, n. 2, p. 233, doi. 10.1111/bjh.13035

By:

Advani, Anjali S.;
McDonough, Shannon;
Copelan, Edward;
Willman, Cheryl;
Mulford, Deborah A.;
List, Alan F.;
Sekeres, Mikkael A.;
Othus, Megan;
Appelbaum, Frederick R.

Publication type:

Article

SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.

Published in:

British Journal of Haematology, 2014, v. 166, n. 1, p. 1, doi. 10.1111/bjh.13035

By:

Advani, Anjali S.;
McDonough, Shannon;
Copelan, Edward;
Willman, Cheryl;
Mulford, Deborah A.;
List, Alan F.;
Sekeres, Mikkael A.;
Othus, Megan;
Appelbaum, Frederick R.

Publication type:

Article